EffRx Supports the 16th Annual Rare Disease Day on 28. February 2023
The product portfolio is led by already commercialized Binosto® for the treatment of postmenopausal osteoporosis.
EffRx Pharmaceuticals Signs Exclusive Licensing Agreement With Radius Health To Commercialize BINOSTO® In The United States
Freienbach, September 19th, 2023 – EffRx Pharmaceuticals SA, a commercial-stage pharmaceutical company focused on the development and commercialization of musculoskeletal and rare diseases medications, today announced …